Article

Bispecific nanobody® as new pharmacological drug for the selective inhibition of Trypsin-3

2024-12-03

Abstract excerpt

<h4>Background: </h4> and Purpose Proteolytic balance is dysregulated in many diseases, with proteases playing critical roles in pathological pathways. A high level of Trypsin-3 expression has been implicated as a significant mediator of tumour progression and metastasis and this protease is associated with poor prognosis for patient in various cancers. Therefore, Trypsin-3 inhibition has emerged as a promising th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d6e4843d-bde9-505b-9b8d-dade61fde894
DOI: 10.22541/au.173322563.37284703/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Bispecific nanobody® as new pharmacological drug for the selective inhibition of Trypsin-3DOI 10.22541/au.173322563.37284703/v1Read

A Nanobody as a Potent Angiogenesis Inhibitor That Targets the Orphan Receptor Tie1Semantic proximity Read

Protease-Containing Nanobodies for Detecting and Manipulating Intracellular Antigens Using Antiviral DrugsSemantic proximity Read

Highly reliable GIGA-sized synthetic human therapeutic antibody library constructionSemantic proximity Read

Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens.Semantic proximity Read

Structural insight into distinct mechanisms of protease inhibition by antibodiesSemantic proximity Read

Rational Design of a Humanized Antibody Inhibitor of Cathepsin BSemantic proximity Read

Development and characterization of Novel Small Molecule Inhibitors Targeting LAG-3 ProteinSemantic proximity Read

Development and Differentiation in Monobodies Based on the Fibronectin Type 3 DomainSemantic proximity Read

Characterization of Affitin proteolytic digestion in biorelevant media and improvement of their stabilities via protein engineering.Semantic proximity Read

Biomolecular recognition of the glycan neoantigen CA19-9 by distinct antibodiesSemantic proximity Read

Smaller size packs a stronger punch - Recent advances in small antibody fragments targeting tumour-associated carbohydrate antigensSemantic proximity Read

Screening and Characterization Strategies for Nanobodies Targeting Membrane Proteins.Semantic proximity Read